MIRA Pharmaceuticals Announced New Insights Garnered From Additional, Recently Received Preclinical Study Data Regarding The Mechanism Of Action And Toxicology Data For Its Oral Ketamine Analog, Ketamir-2
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals announced new insights from recent preclinical study data on its oral ketamine analog, Ketamir-2. The positive data is a step towards potential IND submission this year.
July 25, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals announced new positive preclinical data for its oral ketamine analog, Ketamir-2, which is a step towards potential IND submission this year.
The positive preclinical data is a significant milestone for MIRA Pharmaceuticals as it progresses towards an IND submission. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100